Cytokinetics Announces Eleven Abstracts to Be Presented at the 44th Annual American Society of Cell Biology Meeting.SOUTH SAN FRANCISCO South San Francisco, city (1990 pop. 54,312), San Mateo co., W Calif.; inc. 1908. South San Francisco has several industrial parks; its manufactures include medical supplies and equipment, foods, paint, paper products, consumer goods, and clothing. , Calif. -- Cytokinetics, Inc. (Nasdaq:CYTK) announced today that eleven abstracts relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc its research programs will be presented at the 44th Annual American Society of Cell Biology Cell biology The study of the activities, functions, properties, and structures of cells. Cells were discovered in the middle of the seventeenth century after the microscope was invented. (ASCB ASCB American Society for Cell Biology ASCB Avionics Standard Communication Bus ASCB Address Space Control Block (MVS) ASCB Arbitrarily-Shaped Conducting Body ) meeting in Washington, DC. Details regarding the scientific presentations are provided below:
Sunday, December 5, 12:00 - 3:00 pm
1. Abstract #174: Activation of Cardiac Sarcomere ATPase by
CK-1122534, a Small Molecule Agent that Specifically Targets
Cardiac Myosin (Session 117, Muscle and Muscle-Associated
Proteins I)
2. Abstract #198: Structure of Human Kip3d - Unconventional
Microtubule Depolymerizing Kinesin (Session 118, Kinesin I)
3. Abstract #199: Regulation of ATPase Activity of Internal Motor
Kinesin, pKinI: Binding to Microtubule Lattice is Non-productive
(Session 118, Kinesin I)
Tuesday, December 7, 12:00 - 3:00 pm
1. Abstract #1480: Identification and Characterization of Candida
Albicans Formins (Session 316, Actin Dynamics and Assembly II)
2. Abstract #1489: Regulation of WASP and N-WASP by Different
Activators (Session 316, Actin Dynamics and Assembly II)
3. Abstract #1498: Interaction of Myosin with Blebbistatin Reported
by Fluorescence Spectroscopy (Session 317, Conventional Myosin)
4. Abstract #1499: The Cardiac Myosin Activator, CK-1122534,
Overcomes the Myosin II Inhibitors 2, 3-Butanedione-2-Monoxime and
(-)-S-Blebbistatin without Affecting the Ca(2+) Transient in
Ventricular Myocytes (Session 317, Conventional Myosin)
5. Abstract #1500: The Cardiac Myosin Activator, CK-1122534,
Increases Contractility in Adult Cardiac Myocytes without Altering
the Calcium Transient (Session 317, Conventional Myosin)
6. Abstract #1501: Cellular Responses of the Myosin Activator
CK-0689705 in Normal and Heart Failure Models (Session 317,
Conventional Myosin)
Wednesday, December 8, 12:00 - 3:00 pm
1. Abstract #2128: Vasodilator-Stimulated Phosphoprotein (VASP)
Promotes Arp2/3 Complex Mediated Actin Polymerization, Prevents
Branching and Stabilizes Actin Filaments (Session 416, Actin
Dynamics and Assembly III)
2. Abstract #2191: A High Throughput Screen for Inhibitors of
Microtubule Depolymerizing Enzyme from Plasmodium Falciparum
(Session 419, Microtubule Dynamics and Assembly II)
About Cytokinetics Cytokinetics is a leading biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that specifically target the cytoskeleton cytoskeleton System of microscopic filaments or fibres, present in the cytoplasm of eukaryotic cells (see eukaryote), that organizes other cell components, maintains cell shape, and is responsible for cell locomotion and for movement of the organelles within it. . The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Cytokinetics' focus on the cytoskeleton enables it to develop novel and potentially safer and more effective classes of drugs directed at treatments for cancer, cardiovascular disease Cardiovascular disease Disease that affects the heart and blood vessels. Mentioned in: Lipoproteins Test cardiovascular disease , fungal diseases fungal diseases or mycoses Diseases caused by any fungus that invades the tissues. Superficial fungal infections (e.g., athlete's foot) are confined to the skin. and other diseases. Cytokinetics has developed a cell biology driven approach and proprietary technologies to evaluate the function of many interacting proteins in the complex environment of the intact human cell. Cytokinetics employs the PUMA(TM) system and Cytometrix(TM) technologies to enable early identification and automated prioritization of compounds that are highly selective for their intended protein targets without other cellular effects, and are thereby less likely to give rise to clinical side effects Side effects Effects of a proposed project on other parts of the firm. . Cytokinetics and GlaxoSmithKline have entered into a strategic alliance to discover, develop and commercialize small molecule therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. targeting human mitotic mitotic pertaining to mitosis. mitotic activity degree to which a cell population is proliferating; used as an index of tumor aggression. kinesins for applications in the treatment of cancer and other diseases. GlaxoSmithKline is conducting Phase II and Phase Ib clinical trials for SB-715992 and a Phase I clinical trial Noun 1. phase I clinical trial - a clinical trial on a few persons to determine the safety of a new drug or invasive medical device; for drugs, dosage or toxicity limits should be obtained phase I for SB-743921, each a drug candidate that has emerged from the strategic alliance. Additional information about Cytokinetics can be obtained at www.cytokinetics.com. This press release contains forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. for purposes of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, statements relating to the expected timing, scope and results of our clinical development and research programs and statements regarding the potential benefits of our drug candidates and potential drug candidates and the enabling capabilities of our proprietary technologies. Such statements are based on management's current expectations, but actual results may differ materially due to various factors. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of Cytokinetics' drug candidates that could slow or prevent clinical development, product approval or market acceptance (including the risks related to uncertainty of patent protection for Cytokinetics' intellectual property or trade secrets, Cytokinetics' ability to obtain additional financing if necessary and unanticipated research and development and other costs). For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion